Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724202 · ClinicalTrials.gov registry record · Early Phase 1
Curcumin in Combination With 5FU for Colon Cancer
A Early Phase 1 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT02724202 is a Early Phase 1 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 15 participants.
The verdict
NCT02724202, a Early Phase 1 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what effects (good and bad) that the combined treatments have on colon cancer.
Interventions
- DRUG Curcumin
- DRUG 5-flurorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2020-01-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02724202
The ClinicalTrials.gov registry entry for NCT02724202 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Curcumin is the first listed.
NCT02724202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02724202 about?
NCT02724202 is a clinical study titled "Curcumin in Combination With 5FU for Colon Cancer". The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what effects (good and bad) that the combined treatments have on colon cancer.
What is the current status of trial NCT02724202?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2018-02-20. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT02724202?
The interventions under investigation include: Curcumin (DRUG), 5-flurorouracil (DRUG).
Who is sponsoring clinical trial NCT02724202?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.